A8 (AMENDED) FIG. 1A - FIG. 1B are graphs showing the relationship between the DNA content of normal human peripheral blood mononuclear cells and the amount of fluoresceinated HK-X (f-Met-Leu-Phe-Phe) (SEQ ID NO: 3) binding to the surface of the cells.

On page 13, lines 29 - 30 through to page 14, lines 1-2, please amend the following:

A9 (AMENDED) Preferred VLA6-IMSTPMA agents are certain small peptides having the formula f-Met-Leu-X where X (SEQ ID NO's: 5, 3 and 6) is selected from the group consisting of Tyr, Tyr-Phe (SEQ ID NO: 5), Phe-Phe (SEQ ID NO: 3) and Phe-Tyr (SEQ ID NO: 6).

On page 24, lines 27 - 29, please amend the following:

A10 (AMENDED) The cells were then either exposed to the 100nM FITC-labeled f-Met-Leu-Phe-Phe (SEQ ID NO: 3) (HK-X) or were exposed to a control (vehicle not containing peptide).

IN THE CLAIMS:

Please amend claim 2 as follows:

A11 2. (AMENDED) The method of claim 1, wherein said alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent is a peptide having the formula f-Met-Leu-X where X (SEQ ID NO's: 5, 3 and 6) is selected from the group consisting of Tyr, Tyr-Phe (SEQ ID NO: 5), Phe-Phe (SEQ ID NO: 3) and Phe-Tyr (SEQ ID NO: 6), wherein said peptide is capable binding with an α_6 integrin subunit.

Please amend claim 9 as follows:

A12 9. (AMENDED) The method of claim 1, wherein said peptide is f-Met-Leu-Phe-Phe (SEQ ID NO: 3).

Please amend claim 11 as follows:

A13 11. (AMENDED) The method of claim 10, wherein said alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent is a peptide having the

A13

formula f-Met-Leu-X where X (SEQ ID NO's: 5, 3 and 6) is selected from the group consisting of Tyr, Tyr-Phe (SEQ ID NO: 5), Phe-Phe (SEQ ID NO: 3) and Phe-Tyr (SEQ ID NO: 6).

Please amend claim 14 as follows:

A14

14. (AMENDED) The cell surface complex of claim 13, wherein said alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent is a peptide having the formula f-Met-Leu-X where X (SEQ ID NO's: 5, 3 and 6) is selected from the group consisting of Tyr, Tyr-Phe (SEQ ID NO: 5), Phe-Phe (SEQ ID NO:3) and Phe-Tyr (SEQ ID NO: 6).

Please amend claim 16 as follows:

A15

16. (AMENDED) The method of claim 15, wherein said alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent is a peptide having the formula f-Met-Leu-X where X (SEQ ID NO's: 5, 3 and 6) is selected from the group consisting of Tyr, Tyr-Phe (SEQ ID NO: 5), Phe-Phe (SEQ ID NO: 3) and Phe-Tyr (SEQ ID NO: 6).

Please amend claim 19 as follows:

A16

19. (AMENDED) The cell surface complex of claim 18, wherein said alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent is a peptide having the formula f-Met-Leu-X where X (SEQ ID NO's: 5, 3 and 6) is selected from the group consisting of Tyr, Tyr-Phe (SEQ ID NO: 5), Phe-Phe (SEQ ID NO: 3) and Phe-Tyr (SEQ ID NO: 6).

Please amend claim 21 as follows:

A17

21. (AMENDED) The method of claim 20, wherein said alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent is a peptide having the formula f-Met-Leu-X where X (SEQ ID NO's: 5, 3 and 6) is selected from the group consisting of Tyr, Tyr-Phe (SEQ ID NO: 5), Phe-Phe (SEQ ID NO: 3) and Phe-Tyr (SEQ ID NO: 6).